A detailed history of Charles Schwab Investment Management Inc transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 75,495 shares of FHTX stock, worth $363,885. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,495
Previous 68,495 10.22%
Holding current value
$363,885
Previous $393,000 78.63%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.8 - $9.99 $33,600 - $69,930
7,000 Added 10.22%
75,495 $702,000
Q2 2024

Aug 12, 2024

BUY
$5.05 - $8.0 $65,917 - $104,424
13,053 Added 23.54%
68,495 $393,000
Q2 2023

Aug 09, 2023

BUY
$5.37 - $8.84 $2,754 - $4,534
513 Added 0.93%
55,442 $390,000
Q4 2022

Feb 13, 2023

BUY
$5.44 - $9.46 $9,933 - $17,273
1,826 Added 3.44%
54,929 $350,000
Q3 2022

Nov 14, 2022

SELL
$7.52 - $18.01 $180 - $432
-24 Reduced 0.05%
53,103 $456,000
Q2 2022

Aug 15, 2022

BUY
$8.48 - $16.84 $10,659 - $21,167
1,257 Added 2.42%
53,127 $723,000
Q1 2022

May 13, 2022

BUY
$8.87 - $22.1 $9,393 - $23,403
1,059 Added 2.08%
51,870 $790,000
Q4 2021

Feb 11, 2022

BUY
$10.79 - $22.87 $9,203 - $19,508
853 Added 1.71%
50,811 $1.16 Million
Q3 2021

Nov 16, 2021

SELL
$8.33 - $15.02 $178,286 - $321,473
-21,403 Reduced 29.99%
49,958 $696,000
Q2 2021

Aug 16, 2021

BUY
$9.32 - $13.26 $221,424 - $315,031
23,758 Added 49.91%
71,361 $762,000
Q1 2021

May 17, 2021

BUY
$11.8 - $23.11 $19,434 - $38,062
1,647 Added 3.58%
47,603 $628,000
Q4 2020

Feb 16, 2021

BUY
$15.12 - $25.88 $694,854 - $1.19 Million
45,956 New
45,956 $932,000

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $201M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.